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INTRODUCTION
The link existing between the upper and lower airways has 
been observed repeatedly in the past, but the concept of united 
airways disease (UAD) is a matter of recent years,
1 thanks to the 
increasingly detailed pathogenic knowledge acquired over the 
last 15 years. Nevertheless, in daily practice, the nose and lungs 
are treated as separate entities and by two different specialists.
Each portion of the respiratory tree has specific tasks, such as 
humidification, air filtration, warming, and perceiving perfumes 
and odors for the nose; phonation for the larynx; and gas ex-
change for the lungs. However, clinical signs and diseases af-
fecting both nose and bronchi are often common, as asthma 
and rhinitis. In fact, nasal and bronchial diseases often coexist 
and Upper Respiratory Tract Infections (URTI) are capable of 
exacerbating asthma,
2 while rhinitis has been identified as an 
independent risk factor for asthma development.
3 The upper 
and lower respiratory tracts form a continuum and share many 
anatomical and histological properties and an important fea-
ture: the passage of air into and out of the lungs. In addition, the 
upper and lower airways also share a common susceptibility to 
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different agents, such as allergens, infections, pollutants related 
to occupational exposures, certain drugs; and respond to these 
elements in a similar way. The surface of the whole tract is char-
acterized by a ciliate epithelium with mucinous glands associ-
ated and by a dense network of vascularization and innerva-
tion.
4 Particularly considering innervation, it surely seems very 
similar all along the respiratory tract, supporting the hypothesis 
of the so-called sinu-nasal-bronchial reflex as a possible com-
mon pathogenetic mechanism.
5,6
The natural progression of respiratory allergy commonly starts 
from the upper respiratory tract and later spreads to the lower 
tract.
7 Allergic patients suffer from a general inflammatory sta-
tus interesting the whole respiratory tract and manifesting 
through several different diseases mainly affecting the nose, the 
paranasal sinuses and the bronchi.
8 Local inflammation may 
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actually play a systemic role via soluble mediators that involve 
the bone marrow,
9 which responds in a rapid and specific way 
to nasal challenge, with an increased production of precursors 
and mature eosinophils.
10,11 Moreover, nasal allergen exposure 
in patients suffering from AR may rapidly lead to a significant 
pulmonary allergic inflammation, even subjects who don’t have 
a history of asthma nor BHR.
12 It has been demonstrated that a 
segmental bronchial challenge may induce nasal symptoms 
and inflammation in patients suffering from AR, 24 hours after 
the test; on the other hand, even after a nasal challenge, a de-
cline in respiratory function may be detected, 4-6 hours after 
the test.
13,14
All these observations have therefore contributed to the gene-
sis of the term UAD, and the respiratory tract is now considered 
as a single entity both morphologically and functionally.
15
Anatomy of the respiratory tract
The respiratory tree is functionally divided between the con-
ductive paths and the portion deputed for gas exchange. Ana-
tomically, it is classically distinguished into nose, mouth, phar-
ynx, larynx, trachea and bronchi, which, in turn, are dichotom-
ically divided until the respiratory bronchioles. These lasts, with 
their air cells, correspond to the respiratory portion reserved for 
pulmonary gas exchange. Conventionally, the respiratory tree 
is divided into two parts: the upper airway and lower airway 
and the larynx is the portion that separates the two areas. The 
upper respiratory tract begins therefore with the nostrils and 
the mouth and ends with the larynx, while the lower tract goes 
from the larynx to the alveoli. The nasal cavity is limited by bones 
and divided into two areas by the nasal septum. These two por-
tions form the anterior nasal passages or nostrils, and posteri-
orly they re join to form a single air cavity in the pharynx. A visi-
ble part, the vestibule, and an inner part, which represents the 
main portion of the nasal cavity, form the nose. In the main na-
sal cavity, three bones form the nasal choanae and they increase 
the inner surface of the nose, while reducing the lumen at the 
same time. This conformation allows a close contact between 
the inhaled air and the nasal mucosa, resulting in humidifica-
tion and heating of the air. In addition, the turbulent flow of the 
air allows the deposition of particles on the nasal cavity, so that 
this area of the respiratory tract has an action of filtration as 
well.
16 The nasal sinuses, which communicate with the nasal 
cavity, are involved in thermal regulation of the inhaled air.
17
After the nasal cavity, the pharynx communicates with the lar-
ynx, which is the organ of phonation, but it is also a valve that 
protects the airways and lungs from a possible passage of for-
eign bodies.
18 The larynx ends in the trachea, which is formed 
by regular cartilaginous rings without a back cartilaginous wall. 
This configuration allows the trachea both to prevent collapse 
in case of an abrupt rise in intrathoracic pressure and to de-
crease the pressure when it suddenly increases to efforts such 
as coughing. Distally, the trachea is divided into two bronchi, 
the right and the left one.
The main bronchi have a cartilage structure as well. They di-
vide dichotomically into bronchioles, in successive generations. 
As the bronchi become smaller, even the cartilage becomes 
thinner until it disappears in the bronchioles. After the terminal 
bronchioles, there are the respiratory bronchioles and the air 
cells that constitute the area of the lungs deputed to gas ex-
change.
Reactions triggers
Several factors may trigger reflex airways reactions. Viruses 
and bacteria are responsible for infectious rhinitis, rhinosinus-
itis, bronchiolitis and pneumonia. They may even cause exac-
erbations in patients suffering from Chronic Obstructive Pul-
munary Disease (COPD) and asthma.
19 Cigarette smoke and 
pollutants, atmospheric or professional, may damage the epi-
thelium as well, and they may be responsible for a chronic in-
flammation such as chronic bronchitis and induce metaplasia 
and cancerous lesions in the upper and lower respiratory tract. 
Tobacco smoke is the most important risk factor of COPD,
20 
cancer of the larynx, bronchial cancer, but also of rhinitis.
21 In-
halation of cadmium smoke from an occupational exposure to 
can lead to emphysema,
22 while exposure to asbestos can lead 
to cancer. These are just some examples of stimuli that can lead 
to a high or low respiratory morbidity. Air pollutants such as ni-
tric dioxide, sulfuric dioxide or particles may be responsible for 
exacerbations of COPD.
23
Allergens are potent stimuli of allergic rhinitis and asthma. 
The rates of indoor allergens such as dust mites or animal pro-
teins, are highly correlated with asthma.
24 The rates of outdoor 
allergens such as pollen are more often associated with rhini-
tis.
25 Pollen particles are generally too large to penetrate the 
lower respiratory tract, but it has been shown that pollen grains 
can be found in bronchial secretions and lung parenchyma.
25 
Asthma and rhinitis are hypersensitivity reactions, which can 
also be triggered by drugs such as beta-blockers or aspirin, cold 
dry air exposure, physical exercise or different professions.
26,27
The molecular weight of particles and substances that lead to 
nasal reactions is higher in the nose than in the bronchi, be-
cause the nose acts as a filter that receives and modifies the 
composition of the air. However, in case of nasal obstruction, 
the inspired air, which penetrates the bronchi, is neither heated 
nor purified and can therefore damage the bronchial epitheli-
um. An upper airways alteration may lead to clinical manifesta-
tions of nasal disease, but it may also lead to lower respiratory 
tract morbidities.
28 Particles are rapidly removed from the nasal 
lumen, thanks to the important vascularization, while the elim-
ination of the same needs much more time in the lower respi-
ratory tract. Low molecular weight antigens produce therefore 
much more intense inflammatory reactions in the bronchial 
district.Nose and Bronchi
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Allergic rhinitis and asthma
Allergic rhinitis is considered a risk factor for developing asth-
ma, but it is possible that this term is not totally correct in the 
sense that this condition may represent an early stage of UAD 
that can progress to full-blown asthma.
4
Allergic rhinitis (AR) is the most common of all atopic diseas-
es and it can develop at any age; nevertheless, most patients re-
port the onset of symptoms before 30 years of age, during some 
of the most productive years of life.
29
AR was initially subdivided on the basis of the time of expo-
sure, into seasonal, perennial and occupational diseases. Since 
the publication of the Allergic Rhinitis and its Impact on Asth-
ma (ARIA) project, the terms intermittent and persistent were 
introduced and a new grading of severity (mild and moderate/
severe) was proposed too; with such a classification, the persis-
tent type describes a distinct group with characteristics that dif-
ferentiate them from intermittent allergic rhinitis.
30
AR is now recognized to be characterized by more than the 
classic symptoms of sneezing, rhinorrhea, and nasal obstruc-
tion. In fact, it is well known that it is associated with impair-
ments in how patients function in day-to-day life at home, at 
work, and in school.
30 Patients may also be bothered by sleep 
disorders, emotional problems, impairment in activities, and 
social functioning.
30
Asthma is defined as a disease of reversible airway obstruc-
tion and is diagnosed by using measures of lung function and 
bronchial hyperreactivity.
31 Clinical manifestations include dry 
cough, expiratory wheezing, chest tightness and dyspnoea, 
which are intermittently triggered by allergens, infections and 
airways irritants.
32
The natural history of asthma is still poorly characterized; how-
ever, we know that a small proportion of asthmatic patients have 
a most severe form that requires, despite new and improved in-
halation therapies, a continuous and long-term treatment with 
oral corticosteroids to control symptoms.
33 Since difficult asth-
ma is rare in childhood, when an asthma is difficult to treat and 
poorly controlled, a special evaluation should include the re-
view of diagnosis with accurate lung function and the evalua-
tion of possible comorbidities.
Allergic rhinitis (AR) is frequently associated with asthma and 
it often precedes bronchial hyper-reactivity.
4 Approximately 
19%-38% of patients with AR have concomitant asthma and 
30%-80% of asthmatics have AR, although these figures proba-
bly underestimate the phenomenon, as recent surveys found 
symptoms of rhinitis in 98.9% of allergic asthmatics and in 78.4% 
of non-allergic asthmatics.
34 A large proportion of patients with 
AR (up to 80% of cases) show bronchial hyperreactivity (BHR), 
even though they do not present any clinical sign of lung func-
tion impairment nor of asthma
35,36 and such a finding may rep-
resent a prognostic factor for further progression to asthma.
37 In 
fact, BHR, which is a paramount feature of asthma, may be con-
sidered as a strong risk factor for the onset of asthma in patients 
presenting with AR.
38,39
Small airway disease (SAD), defined as a reduction in forced 
expiratory flow (FEF) at 25%-75% of the pulmonary volume 
and a normal spirometry, is suggested to be a marker of early 
allergic or inflammatory involvement of the small airways in 
subjects with allergic diseases and no asthma.
4 FEF25-75 seems 
to be significantly associated with BHR, and it has been proposed 
as an early marker of bronchial involvement in patients with AR 
who perceive only nasal symptoms.
40
In those patients concomitantly presenting with both AR and 
asthma, a significantly higher number of aeroallergen sensiti-
zations may be detected than in those without asthma, and pa-
tients suffering from perennial rhinitis present an increased risk 
to develop asthma.
41
Rhinosinusitis and asthma
The coexistence of sinusitis and asthma, particularly in chil-
dren, has been known for several years; the involvement of pa-
ranasal sinuses is considered to be very important for the devel-
opment of lower respiratory tract diseases.
42,43 However, whether 
rhinosinusitis is actually a precipitating factor for bronchial 
asthma is still debated.
33 Rhinosinusitis and asthma seem to be 
two different expressions of a common pathological process, 
not always affected by allergy, in which eosinophils and the air-
way epithelium play a central role.
33 Recent progress in under-
standing the biology of airway disease has identified inflamma-
tion as the key to understand these diseases. Nevertheless, sev-
eral other mechanisms that link the upper (nose, sinuses, lar-
ynx, pharynx, and trachea) and lower (bronchi and lungs) air-
way segments may be involved too.
44
Rhinosinusitis is a common disease that may be present in 
the pediatric population and may influence the clinical course 
of asthma by a variety of mechanisms.
45 In facts, sinonasal pa-
thology is recognized to be one of the most common comor-
bidity among asthmatic patients.
46 Symptoms include nasal 
congestion, nasal discharge, nasal purulence, postnasal drip, 
facial pressure, hyposmia, cough, fever, halitosis, dental pain, 
ear fullness, and headache. The diagnosis and management of 
sinusitis are often challenging, but generally unsatisfactory.
47
The term sinusitis refers to the presence of inflammation 
within any of the four pairs of paranasal sinuses. The pathogen-
esis of this disease is poorly understood. The long-term conse-
quences of chronic sinusitis may include lose of mucociliary 
clearance and of other physiologic mechanisms that normally 
maintain the relative sterility of the sinuses.
47
In facts, rhinosinusitis coexists with asthma in 34%-50% of pa-
tients.
48 Nevertheless, in patients presenting with asthma, the 
incidence of concomitant rhinosinusitis rise up to 84%, espe-
cially during asthma exacerbations.
48 The observation that asth-
ma and rhinosinusitis coexist in patients at a higher frequency 
than would be expected from the prevalence of each in the gen-
eral population provides a strong connection between the up-Ciprandi et al.
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per and lower airways.
45 Sinonasal disease in asthmatics ap-
pears to differ somewhat from that of the general population 
and the temporal sequence of disease and parallel inflammato-
ry pathways involved suggest that they may be progressive man-
ifestations of a common disease process.
46 Precipitants of asth-
ma are generally also precipitants of sinusitis, and, therefore, 
the association of sinusitis with asthma exacerbations may be 
an epiphenomenon.
47
It is not clear whether rhinosinusitis is a direct trigger for asth-
ma or if the two conditions are just manifestations of a common 
underlying process. Possible explanations for the observed as-
sociation of rhinosinusitis and asthma may include the naso-
bronchial reflex, pharyngobronchial reflex, postnasal drainage 
of inflammatory mediators from the upper to lower airway, in-
halation of dry, cold air and environmental pollutants, and the 
“shared pathogenesis” of rhinosinusitis and asthma.
31 Even the 
bone marrow may provide this link between the upper and 
lower airways in creating a common disease: blood eosinophil 
count is often increased in asthma and correlates with severity 
of asthma, while IL-5 may be a key cytokine for orchestrating 
the systemic interaction.
31,48
Current evidence suggests that rhinosinusitis without either 
polyps or eosinophilic inflammation is a direct trigger for asth-
ma, whereas rhinosinusitis with both polyps and eosinophilic 
inflammation shares underlying mechanisms with asthma.
32 
There is also evidence that markers of bronchial inflammation, 
typically monitored in asthmatics, correlate with the severity of 
sinusitis.
49
The two diseases are inflammatory processes in which eosin-
ophils and the airway epithelium play a central role: eosinophils 
are thought to damage the epithelium by releasing cytokines 
and other pro-inflammatory proteins. The damaged epitheli-
um then react by releasing cytokines and chemokines that fur-
ther attract eosinophils, thus starting a vicious circle of actions 
and reactions that activates and sustains inflammation.
33
Treating the nose and the lungs
Nasal and inhaled steroids
Nasal steroids are a great tool for controlling symptoms in pa-
tients with AR and treating patients suffering from rhinosinus-
itis. These drugs, especially when combined with inhaled ste-
roids, are capable of reducing both bronchial hyper-reactivity 
in asthmatic patients and recurrence to the emergency depart-
ment for exacerbation and hospitalization.
50,51
Nowadays, treating rhinitis is essential to manage asthma 
symptoms as well, meaning that asthma and rhinitis, in some 
patients, may be controlled by the exclusive use of nasal medi-
cation.
52 The hypothesis that nasal inhalation of a corticosteroid 
can be effective both for rhinitis and asthma was examined with 
positive findings in several studies where budesonide had been 
nasally administered, resulting in both upper and lower air-
ways deposition.
53 Alternatively, exhaling a budesonide inhaler 
through the nose results in a significant reduction in dose re-
quirement of budesonide nasal spray in patients who have 
asthma with rhinitis.
54
Nevertheless, the definition of a realistic extent of effect of na-
sal steroids on asthma control appears rather uncertain and 
further researches should be performed to evaluate the effects 
of intranasal corticosteroids on asthma control; a combination 
of intranasal and intrabronchial corticosteroids should contin-
ue to be used in clinical practice until more research is carried 
out.
Antihistamines
Antihistamines are very helpful in controlling symptoms of 
AR or of allergic rhino-conjunctivitis, mainly in association with 
nasal steroids. During the pollen season, antihistamine treat-
ment reduces the symptoms of asthma.
55 Nevertheless, it is clear 
that they do not affect asthma, even though their beneficial ac-
tion on the upper airway contributes to improve the overall 
management of the one airway disease.
56
In children, the occurrence of respiratory infections and exac-
erbations of asthma may be reduced by continuous antihista-
mine treatment.
57,58
Leukotriene receptor antagonists (LTRAs)
The purpose of prescribing an antileukotriene treatment in 
patients with both AR and asthma is to reduce the inflamma-
tion of both the nasal and bronchial mucosae, and to improve 
the total symptoms score of both conditions. Several studies 
have actually showed that LTRAs are effective in treating both 
the upper and lower airways in patients with asthma and 
AR.
59,60
Specific immunotherapy
Specific immunotherapy, either sublingual or subcutaneous, 
is prescribed in patients suffering from AR or asthma or both. 
Such a treatment results in lower asthma symptoms and re-
duced use of medication during the second and third years of 
therapy, associated with a reduction in asthma development 
and in nonspecific BHR.
61 The apparent success of specific im-
munotherapy in children with AR in preventing the develop-
ment of asthma and BHR provides a powerful argument sup-
porting a common pathogenetic mechanism in allergic respi-
ratory disease.
62
Nevertheless, further investigations are needed in order to 
confirm the preventative role of specific immunotherapy.
CONCLUSIONS
The idea of a one airway disease is the key concept of the ARIA 
document, and has relevant implications for the diagnostic and 
therapeutic management of respiratory allergy. Several studies 
have shown that in patients with asthma who have a seasonal Nose and Bronchi
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rhinitis, an increase in bronchial hyper-reactivity may be out-
lined. There is also an infiltration of the bronchial mucosa by 
neutrophils. Furthermore, in patients with asthma and rhinitis, 
the treatment of rhinitis leads to an improvement of respiratory 
symptoms.
ARIA document has clearly underlined, throughout these last 
10 years, the role of AR as a risk factor for asthma and suggests 
to always consider bronchial involvement in patients present-
ing with AR.
2 On the other hand, even the Global Initiative for 
Asthma (GINA) advises to evaluate asthmatic patients for nasal 
involvement as well.
63 In clinical practice, therefore, it should be 
now clear that, when evaluating a patient presenting with AR, 
doctors should perform respiratory function test or at least pose 
questions to evaluate a possible concomitant bronchial involve-
ment; on the other hand, patients suffering from asthma 
should always receive a nasal treatment as well.
The role played by sinus disease in asthma is only partly un-
derstood, largely owing to deficits in the clinical classification 
and in basic knowledge of pathophysiological pathways. Nev-
ertheless, it is now clear the existence of a causal relationship 
between sinusitis and asthma. If, on one hand, the treatment of 
sinusitis leads to a symptoms improvement in asthmatic pa-
tients, on the other hand, sinusitis seems to induce a worsening 
of asthma. Thus, it seems clear that rhinosinusitis and asthma 
represent a range of overlapping diseases with a similar patho-
physiological mechanism, where chronic airway mucosal in-
flammation and remodeling are playing a critical and integrat-
ing role in these diseases.
48
It can be suggested that rigorous treatment of comorbid fac-
tors, such as rhinosinusitis, could result in less asthma exacer-
bations, which will greatly improve the quality of life of these 
difficult-to-control patients with asthma.
64
In general, there is a strong interaction between the upper and 
lower respiratory tract which may be due to a loss of power fil-
tering and protection functions of the nose, an interaction of 
neurotransmitters or the spread of inflammation of the lower 
respiratory tract.
65-68 There is also an infiltration of the nasal mu-
cosa by eosinophils in asthmatic patients without rhinitis and 
bronchial segmental challenge with allergen leads to an increase 
in nasal airways resistance. In general, therefore, not only URTI 
lead to lower airways inflammation, but even the other way is 
true. All these considerations reinforce the theory that there is 
one and unique respiratory system that reacts as a single body 
at the same time.
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